David A. Siegel Aadi Bioscience, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 31,600 shares of AADI stock, worth $90,376. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,600
Previous 15,300
106.54%
Holding current value
$90,376
Previous $22,000
195.45%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AADI
# of Institutions
55Shares Held
12.6MCall Options Held
23.8KPut Options Held
0-
Avoro Capital Advisors LLC New York, NY2.85MShares$8.15 Million0.09% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2MShares$5.72 Million2.42% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$5.29 Million3.86% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA1.85MShares$5.28 Million0.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA766KShares$2.19 Million0.0% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $60.1M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...